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Abstract
Melatonin, an evolutionarily ancient derivative of serotonin with hormonal properties, is the main 
neuroendocrine secretory product of the pineal gland. Although melatonin is best known to 
regulate circadian rhythmicity and lower vertebrate skin pigmentation, the full spectrum of 
functional activities of this free radical-scavenging molecule, which also induces/promotes 
complex antioxidative and DNA repair systems, includes immunomodulatory, thermoregulatory, 
and antitumor properties. Because this plethora of functional melatonin properties still awaits to be 
fully appreciated by dermatologists, the current review synthesizes the main features that render 
melatonin a promising candidate for the management of several dermatoses associated with 
substantial oxidative damage. We also review why promises to be useful in skin cancer prevention, 
skin photo- and radioprotection, and as an inducer of repair mechanisms that facilitate the recovery 
of human skin from environmental damage. The fact that human skin and hair follicles not only 
express functional melatonin receptors but also engage in substantial, extrapineal melatonin 
synthesis further encourages one to systematically explore how the skin’s melatonin system can be 
therapeutically targeted in future clinical dermatology and enrolled for preventive medicine 
strategies.
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MELATONIN: A JOURNEY THROUGH TIME
The methoxyindole, melatonin (N-acetyl-5-methoxytryptamine), is produced by at least 
three clades of bacteria, all clades of eucarya including dinoflagellates, unicellular and 
multicellular fungi, at least 120 plant species, and numerous animal species including simple 
and complex vertebrates and invertebrates (Back et al., 2016; Hardeland, 2016; Hardeland et 
al., 1995; Pöggeler et al., 1991; Tan et al., 2013, 2014).
The presence of melatonin in Alphaproteobacteria and Cyanobacteria indicates an early 
appearance of this multifunctional serotonin derivative in the evolution of life (Tan et al., 
2012, 2013). The discovery of antioxidative properties of melatonin (Hardeland, 2005, 2017; 
Hardeland et al., 2011; Reiter, 1998; Tan et al., 2002) is consistent with an ancient role of 
this molecule in contributing to survival under high oxygen levels or exposure to UVR. 
Because of melatonin production in mitochondria (Reiter et al., 2017b; Suofu et al., 2017; 
Tan et al., 2013), scavenging of free oxygen radicals has likely been a primary role of 
melatonin in evolution (Hardeland et al., 1995) originating around 2.5–3 billion years ago 
(Reiter et al., 2017; Tan et al., 2015).
In all organisms, melatonin is formed from tryptophan via serotonin, with taxon-specific 
variations in the sequence of steps and intermediates (Back et al., 2016; Hardeland, 2015, 
2016; Tan et al., 2012, 2014, 2015, 2016) (Supplementary Text S1 online).
In vertebrates, melatonin is mainly perceived as the hormone of the pineal gland (Lerner et 
al., 1958 Reiter, 1991). The mammalian pineal gland represents the major source of 
melatonin in the blood, and in the cerebrospinal fluid of the third ventricle of the brain, 
where it contributes to the regulation of the circadian system (Reiter et al., 2014). Melatonin 
is also synthesized in numerous extrapineal sites such as brain, Harderian gland, retina, lens, 
cochlea, immune system, lungs, gastrointestinal tract, liver, kidney, thyroid, pancreas, 
thymus, spleen, carotid body, reproductive tract, endothelial cells, and skin (Acuña-
Castroviejo et al., 2014; Hardeland et al., 2011; Slominski et al., 2008 Vanegas et al., 2012). 
Melatonin levels are regulated by its rapid metabolism in the liver or peripheral organs 
including skin (Slominski et al., 2017b).
Since its origin in early unicells, melatonin, while protecting against oxidative stress, has 
acquired numerous functions that are taxon, species, and tissue specific. In vertebrates, these 
functions are manifold and complex, with melatonin acting as a pleiotropic regulator of 
numerous parameters that orchestrate complex cell and tissue responses, both directly and 
indirectly (via the circadian system) (Hardeland et al., 2011; Tan et al., 2015). A full record 
of these functions is summarized elsewhere (Hardeland et al., 2011; Pandi-Perumal et al., 
2006; Tan et al., 2015).
MELATONIN IN THE SKIN
Production and metabolism
Normal and pathological skin not only expresses enzymatic elements of the pathway but can 
also produce serotonin, N-acetylserotonin, and melatonin with its metabolites (Kim et al., 
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2013, 2015a, 2015b; Kobayashi et al., 2005; Nordlind et al., 2008; Schallreuter et al., 2012; 
Semak et al., 2004; Slominski et al., 1996, 2002a, 2002b, 2002c, 2003a, 2005c, 2008) 
(Supplementary Figure S1 online). Skin can also synthesize/recycle the (6R)-L-
erythro-5,6,7,8-tetrahydrobiopterin, a cofactor for tryptophan hydroxylase (TPH; Grando et 
al., 2006; Schallreuter et al., 1997, 1998). Hydroxytryptophan can also be generated in the 
skin nonenzymatically through H2O2 and UVA-induced free-radical-mediated oxidation of 
L-tryptophan (Schallreuter et al., 2008). In addition to widespread TPH1 gene expression in 
skin cells (Slominski et al., 2002b, 2003a, 2005c), we also detected TPH2 in melanocytes, 
dermal fibroblasts (Slominski et al., 2014b), and retinal pigment epithelium (Zmijewski et 
al., 2009). Skin can also express alternatively spliced forms of the melatonin-synthesizing 
pathway: TPH, arylalkylamine N-acetyltransferase, and N-acetylserotonin-O-
methyltransferase (Slominski et al., 2002b). Cutaneous N-acetylserotonin is produced by 
both arylalkylamine N-acetyltransferase and arylamine N-acetyltransferase (Semak et al., 
2004; Slominski et al., 2002a, 2003b).
Melatonin in skin cells is rapidly metabolized through indolic, kynuric, and P450-dependent 
pathways or via nonenzymatic processes induced by UVR or free radicals (Fischer et al., 
2006a; Kim et al., 2013; Slominski et al., 1996, 2017b) (Supplementary Figure S1).
Although immunocytochemistry identified N-acetylserotonin and melatonin antigens in 
epidermal and follicular keratinocytes and melanocytes, adnexal structures, fibroblasts, 
endothelial cells, and mast cells (Kobayashi et al., 2005; Slominski et al., 2005c, 2008), only 
recently mass spectrometry quantified melatonin and its metabolites in human epidermis 
(Kim et al., 2015a, 2015b). Epidermal melatonin production depends on race, gender, and 
age with the highest melatonin levels in African Americans. Among metabolites, 6-
hydroxymelatonin showed the highest levels followed by 5-methoxytryptamine, N1-acetyl-
N2-formyl-5-methoxykynuramine (AFMK), and N1-acetyl-5-methoxykynuramine (Kim et 
al., 2015a, 2015b). Levels of AFMK and N1-acetyl-5-methoxykynuramine were the highest 
in African Americans, and no racial difference was seen for 6-hydroxymelatonin and 5-
methoxytryptamine. However, skin pathology-related changes in the epidermal content of 
melatonin and its metabolites remain to be systematically explored to dissect the relationship 
between their endogenous production and metabolic consumption and defined skin 
disorders.
Mechanism of action
The potential intracellular targets for melatonin action are shown in Figure 1. The receptor-
dependent regulatory functions of melatonin are mediated through interactions with G 
protein-coupled melatonin type 1 and 2 receptors (MT1 and MT2) (Cecon et al., 2017; 
Slominski et al., 2012). The latter predominantly work by inhibiting production of second 
messengers (cAMP, cGMP), thereby modifying signaling pathways downstream of protein 
kinases A and C, and cAMP response element-binding protein (Dubocovich et al., 2010; 
Slominski et al., 2012) and by activating MAP kinases (discussed in Hardeland, 2009). MT2 
shows a 60% homology in structure to MT1 (Reppert et al., 1996). MT1 and MT2 
homodimerize as well as heterodimerize (Jockers et al., 2008), which can affect the 
pharmacological properties of the receptors (Jockers et al., 2008; Legros et al., 2014). In 
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addition, their activity is modulated by C-terminal phosphorylation, and, in the case of MT1, 
by stabilization via the scaffolding protein MUPP1 and inhibition by heterodimerization 
with GPR50 (Hardeland, 2009).
MT1 and MT2 receptors have been detected in mammalian skin (Fischer et al., 2008a; 
Kobayashi et al., 2005; Singh and Jadhav, 2014; Slominski et al., 1994, 2005c, 2008). 
Human skin predominantly transcribes the MT1 gene, with MT2 showing restricted or 
conditional expression (Slominski et al., 2003c, 2005a). Gene expression and production of 
alternatively spliced or aberrant forms of MT receptors is modulated by UVB and skin 
pathology (Slominski et al., 2003c, 2005a). In contrast, murine skin showed exclusive 
expression of the MT2 gene (Kobayashi et al., 2005; Slominski et al., 2004a). By 
immunocytochemistry, MT1 was detected in the differentiating layers of the epidermis, outer 
and inner root sheaths of the hair follicle (HF), eccrine glands, and blood vessels, whereas 
MT2 was detected in inner root sheath (IRS), eccrine glands, and blood vessels of human 
skin (Fischer et al., 2008a; Slominski et al., 2005a, 2005c).
It remains to be clarified whether there is also a nuclear receptor for melatonin, because the 
originally proposed nuclear melatonin receptor candidate, RORα, which is expressed in skin 
and HFs (Brozyna et al., 2016; Kobayashi et al., 2005; Slominski et al., 2005a, 2014a), has 
turned out to be a receptor for sterols and secosteroids, but not for melatonin (Slominski et 
al., 2014a, 2016c, 2017a).
Melatonin and its metabolites act as free radical scavengers and protectors against oxidative 
stress (Fernández et al., 2015; Fischer et al., 2006c; Galano et al., 2013; Hardeland, 2017; 
Hardeland et al., 2011). Melatonin and its precursor N-acetylserotonin bind to several 
regulatory proteins including quinone reductase 2 (Jockers et al., 2008; Nosjean et al., 2000). 
Quinone reductase 2 protects cells against oxidative stress (Boutin, 2016; Hardeland, 2009), 
against dimethylbenz(a)anthracene-induced skin cancer (Shen et al., 2010), and is required 
for tumor necrosis factor-α-induced apoptosis in keratinocytes (Ahn et al., 2007). The 
capability of melatonin binding to this enzyme (see Kleszczynski et al., 2016) requires 
additional studies.
Calmodulin is another melatonin-binding protein, which may gain physiologically relevant 
affinity after Ca2+ binding and interaction with calmodulin-controlled enzymes, such as 
calmodulin kinase II and calcineurin, which regulate intracellular calcium homeostasis 
(Fernández et al., 2015; Fukunaga et al., 2002; Hardeland et al., 2009; León et al., 2000; Lu 
et al., 2015; Romero et al., 1998). These observations may partially explain the roles of 
melatonin in the endoplasmic reticulum stress response, regulation of apoptosis and 
autophagy, and mitochondrial homeostasis (Fernández et al., 2015). Melatonin also regulates 
mitochondrial functions that affect cellular homeostasis (Acuña Castroviejo et al., 2011; 
Semak et al., 2005).
FUNCTIONS OF MELATONIN IN THE SKIN
Figure 2 summarizes melatonin effects on the skin, which depend on the route of delivery.
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Photoprotection
The ancient functions of melatonin and its metabolites as antioxidants or inducers of 
responses against oxidative stress or as protectors of genomic integrity are efficiently 
utilized in the human skin, an organ exposed to different stressors including solar radiation 
(Fischer et al., 2008b; Slominski et al., 2012, 2014b). Because protective effects of 
melatonin against UVR were extensively discussed in Fischer et al. (2008b), Kleszczynski 
and Fischer (2012), Ndiaye et al. (2014), and Slominski et al. (2014b, 2014c), we will focus 
on the most important and novel aspects of melatonin radioprotection.
Melatonin and AFMK protect human epidermal keratinocytes both in cell and organ culture 
against UVB (Fischer et al., 2006a, 2006b, 2008b, 2008c, 2013; Kleszczynski et al., 2011, 
2013, 2015, 2016). In addition to melatonin, N-acetylserotonin, 5-methoxytryptamine, 6-
hydroxymelatonin, AFMK, and N1-acetyl-5-methoxykynuramine protect against or reverse 
UVB-induced damage in keratinocytes and melanocytes (Janjetovic et al., 2014, 2017). 
Similarly, melatonin protects dermal fibroblasts against UVA and UVB (Izykowska et al., 
2009; Lee et al., 2003; Rezzani et al., 2014; Ryoo et al., 2001).
Although the mechanisms underlying these radioprotective and antioxidative activities are 
not fully understood yet (Fischer et al., 2006a; Slominski et al., 2005c, 2014b), recent 
studies implicate the involvement of nuclear erythroid 2-related factor 2 (Janjetovic et al., 
2017; Kleszczynski et al., 2016) and sirtuin 1 (Sirt1) (Lee et al., 2016; Ranieri et al., 2015), 
major regulators of human skin and HF oxidative stress responses, and skin aging (Haslam 
et al., 2017; Jadkauskaite et al., 2017; Vidali et al., 2016). Clinically, topically applied 
melatonin can indeed attenuate skin erythema in healthy human subjects exposed to either 
artificial UVR (Bangha et al., 1996, 1997; Fischer et al., 1999) or natural sunlight (Scheuer, 
2017; Scheuer et al., 2016a), thus demonstrating melatonin’s clinical potential as a protector 
against photodamage.
Anticancer activity
The potent anticancer activities of melatonin through a direct action or regulation of 
circadian rhythms have been discussed in depth elsewhere (Ma et al., 2016; Reiter et al., 
2017; Rondanelli et al., 2013; Su et al., 2017). In vitro and in vivo antimelanoma effects of 
melatonin are established in rodent models (Kadekaro et al., 2004; Narita and Kudo, 1985; 
Otalora et al., 2008; Slominski and Pruski, 1993; Stanberry et al., 1983). Melatonin and its 
metabolites also inhibit the growth of cultured human melanomas (Cabrera et al., 2010; 
Fischer et al., 2006c; Roberts et al., 2000; Souza et al., 2003; Yi et al., 2014; Ying et al., 
1993). This raises the question whether topically applied melatonin and its metabolites may 
be used as adjuvants in difficult-to-resect lentigo maligna or mucosal melanomas.
Clinical trials with high doses of melatonin in late stage of metastatic melanoma suggested 
its beneficial effect through either reduction of side effects of chemotherapy/
chemoimmunotherapy or by enhancing their efficacy (Gonzalez et al., 1991; Lissoni et al., 
1997, 2002). Also, an improvement of disease-free survival was observed in patients treated 
with melatonin after lymph node dissection (Lissoni et al., 1996). Therefore, given its low 
cost, very favorable toxicological profile, and expected low or absent adverse effects, 
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systematic clinical testing of melatonin and/or its metabolites as adjuvants in melanoma 
therapy is both warranted and long overdue.
Melatonin also attenuated benzo[a]pyrene-induced cutaneous sarcomas (Vesnushkin et al., 
2006), squamous cell carcinomas (Deriabina et al., 2010), and papillomas (Kumar and Das, 
2000) in mice. Patients with basal cell and squamous cell carcinomas had lower urinary 
indicators of systemic melatonin production in comparison to controls (Ghaderi et al., 2014). 
Together with its radioprotective function, these additional observations identify melatonin 
as a promising natural product for clinical use in skin cancer prevention and oncological 
therapy, which awaits systematic clinical testing.
Epidermal barrier function and wound healing
Exogenously applied melatonin may enhance the skin barrier (Kim et al., 2013). 
Specifically, melatonin and AFMK in human skin organ culture stimulated expression of 
involucrin and keratin-10 and keratin-14. It also increased proliferative activity of 
keratinocytes in ex vivo skin explants (Kim et al., 2013), consistent with earlier observations 
on murine skin (Slominski et al., 1994). Melatonin can also promote skin wound healing 
(Lee et al., 2014; Ozler et al., 2010; Pugazhenthi et al., 2008; Romic et al., 2016; Song et al., 
2016; Soybir et al., 2003), and can improve the antimicrobial action of wound dressing 
(Romic et al., 2016). Of note, a novel melatonin-mitochondria axis has been proposed 
recently as an important regulator of epidermal homeostasis where melatonin and its 
metabolites coordinate the mitochondrial regulation of epidermal cell destiny by impacting 
on the decision between cell survival, entry into terminal differentiation as a part of 
epidermal barrier formation, or to death by apoptosis to evade malignant transformation 
(Slominski et al., 2017c).
In view of melatonin’s reactive oxygen species-scavenging functions on the one hand, and 
the recently appreciated physiological key role of a tightly controlled burst of reactive 
oxygen species production in tissue repair and regeneration on the other (Kimmel et al., 
2016; Love et al., 2013), one of the functions of the cutaneous melatonin system (Slominski 
et al., 2008, 2017c) may also be to control and fine-tune reactive oxygen species availability 
during wound healing. Thus, preclinical studies on the beneficial role of melatonin and its 
metabolites on epidermal barrier formation and wound healing are warranted.
Pigmentation
Lightening effects of melatonin on the skin of lower vertebrates and inhibition of 
pigmentation in some furry animals are well appreciated (reviewed in Slominski et al., 
2004b, 2005c). Seasonal changes in hair pigmentation have been attributed in part to 
melatonin (reviewed in Fischer et al., 2008a; Slominski et al., 2005b). Attenuation of 
melanogenesis was demonstrated in cultured rodent melanomas (Slominski and Pruski, 
1993; Valverde et al., 1995) and in organ-cultured murine skin (Slominski et al., 1994).
In humans, melatonin and some metabolites showed moderate inhibition of tyrosinase and of 
proliferation of cultured epidermal melanocytes (Kim et al., 2015b). Hardman et al. (2015) 
have shown that the cutaneous circadian clock elements regulate melanogenesis and 
melanocyte activities in human epidermis and HFs. Thus, although there are conflicting 
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results on melatonin functions in human hair and skin pigmentation (McElhinney et al., 
1994; Slominski et al., 2004b, 2005c), locally produced melatonin may play a role in the 
regulation of melanocytic activities via its impact on the peripheral clock. Thus, testing of 
topically applied melatonin during defined circadian windows as an external modulator of 
intracutaneous clock activity is warranted (Slominski et al., 2015).
Finally, in light of the autodestruction and oxidative stress theories of vitiligo pathogenesis 
(Lerner, 1971; Schallreuter et al., 2008), melatonin and serotonin might play a protective 
role in vitiligo pathogenesis (see viewpoint 4 in Schallreuter et al., 2008). This is further 
supported by low expression of TPH1 in vitiligo (Schallreuter et al., 2012). Thus, topical 
supplementation of melatonin and its precursors may be beneficial by ameliorating the 
oxidative environment of vitiligo skin.
Hair follicle
Melatonin can regulate hair growth directly or indirectly (e.g., via modulating the prolactin 
serum level) in several nonhuman species (Fischer et al., 2008a; Slominski et al., 2008), and 
the MT2 expression levels of murine HFs change during HF cycling (Kobayashi et al. 2005). 
Human scalp HFs also synthesize melatonin, and this intrafollicular melatonin synthesis can 
be stimulated by noradrenaline, just as in the pineal gland (Kobayashi et al. 2005). 
Moreover, melatonin may modulate human HF responses to estrogens, because it 
downregulates intrafollicular estrogen receptor expression (Kobayashi et al. 2005). Studies 
on human volunteers have raised the possibility that topically applied melatonin may inhibit 
androgenetic alopecia in women (Fischer et al., 2004, 2012).
Given that melatonin stimulates nuclear erythroid 2-related factor 2 (Janjetovic et al., 2017; 
Kleszczynski et al., 2016) whereas nuclear erythroid 2-related factor 2 activation protects 
human HFs against oxidative stress-induced hair growth inhibition (Haslam et al., 2017), it 
deserves further exploration whether melatonin can protect human hair growth via nuclear 
erythroid 2-related factor 2 induction. That melatonin renders human HFs ex vivo less 
susceptible to chemotherapy-induced damage (Kobayashi et al., 2005) may be related in part 
to this putative protective mechanism. Furthermore, involvement of circadian clock proteins 
in the control of human HF cycling (Al-Nuaimi et al., 2014) and of both epidermal and HF 
pigmentation (Hardman et al., 2015) raises the question whether melatonin can impact on 
the control of human hair growth and pigmentation via modulating peripheral clock activity 
in the skin, just as it does centrally.
Inflammatory dermatoses
The role of melatonin in immunodermatology remains insufficiently defined because both 
immunostimulatory and anti-inflammatory actions of melatonin have been reported 
(Carrillo-Vico et al., 2013; Jahanban-Esfahlan et al., 2017). Yet, key innate skin 
immunocytes such as mast cells express melatonin receptors (Theoharides, 2017) and 
melatonin plays an important role in T-cell fate determination, T-cell-based immune 
pathologies (Ren et al., 2017), and macrophage function (Kadena et al., 2017; Yi and Kim, 
2017).
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Despite a shortage of information on the role of melatonin in inflammatory skin disorders, 
beneficial effects of melatonin have been suggested in atopic dermatitis (Calvo and 
Maldonado, 2016; Marseglia et al., 2014, 2015; Park et al., 2017) and seborrheic dermatitis 
(Fischer et al., 2012), and disturbances in serum melatonin levels were reported in patients 
with psoriasis (Kartha et al., 2014; Mozzanica et al., 1988). Thus, studies that define the role 
of melatonin in chronic inflammatory skin diseases are warranted, and may lead to a 
discovery of beneficial effects similar to those recently described for multiple sclerosis 
(Farez et al., 2015).
Thermoregulation
Melatonin directly or via its circadian effects influences core body and skin temperature 
(Atkinson et al., 2005; Cuesta et al., 2017; Filadelfi and Castrucci, 1996; Kräuchi et al., 
1997; van den Heuvel et al., 1999). It can modify the cutaneous vasodilator response to heat 
(Aoki et al., 2006) and is involved in the fine-tuning of vascular tone and modifies cutaneous 
vasoconstrictor response to whole body skin cooling (Aoki et al., 2008; Kräuchi et al., 
2006). However, it remains unknown whether melatonin also plays a role in sweat gland 
physiology.
CONCLUSIONS AND TRANSLATIONAL PERSPECTIVES
That mammalian skin and HFs not only are prominent melatonin targets but also produce 
and rapidly metabolize this multifunctional methoxyindole to biologically active metabolites 
is of considerable dermatological interest and potentially of great clinical importance for 
future dermatological therapy. Here, we have delineated why sufficient levels of locally 
produced melatonin and its metabolites are required for both optimal skin homeostasis, thus 
preventing skin pathology, and optimal responses to environmental stressors including UVR. 
Therefore, physiological concentration of melatonin will depend on the biological context. 
In fact, the serum melatonin level may be largely irrelevant, because skin produces a much 
larger amount of melatonin for its own use than can be detected in serum (Kim et al., 2015b; 
Slominski et al., 2008), similar to the gastrointestinal system that contains several hundred 
times more melatonin than the pineal gland itself (Bubenik, 2002).
Although we have reviewed here how melatonin and its metabolites can impact on multiple 
aspects of human skin physiology, challenging open questions include how exactly these 
agents affect human skin pigmentation, hair growth, and the development of melanoma and 
nonmelanoma skin cancers mechanistically and under clinically relevant circumstances. This 
still needs to be clarified definitively in appropriately designed clinical studies. The 
translational perspectives that emanate from melatonin’s unique properties in multiple 
oxidative damage control and DNA repair systems and its immunomodulatory properties 
render melatonin an especially attractive candidate agent in the future management of 
dermatoses associated with substantial oxidative, photo-, and radiation-induced damage. 
Melatonin also promises to be useful in skin cancer prevention. In addition, in view of 
melatonin's capability to induce multiple damage reparative mechanisms in skin, the 
potential anti-skin aging properties of melatonin deserve systemic study.
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Given that melatonin is essentially nontoxic, readily available over the counter in different 
formulations, and that many of its metabolites meet the definition of natural products, their 
topical and transepidermal delivery is a promising area for full exploration in future 
dermatotherapy and preventive skin medicine.
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Figure 1. Targets for melatonin action in skin cells
Melatonin, depending on the concentration, binds to membrane-bound receptor MT1 or 
MT2. Subsequent activation of signal transduction cascades stimulates the expression of 
antioxidative enzymes and DNA repair. Melatonin might also be transported to cytoplasm; 
however, the detailed mechanism is not fully understood. In a cell, melatonin at 
concentrations higher than 1 nM interacts with the calcium/calmodulin complex, which 
inhibits NOS1-mediated generation of RNS. On the other hand, melatonin can also interact 
with NQO2 (previously described as MT3) with potential inhibition of ROS/RNS levels. 
Recently, peptide transporter PEPT1/2 was found to be responsible for melatonin transport 
to mitochondria (Huo et al., 2017). Melatonin improves mitochondrial membrane potential 
(Δψm) by inhibition of the mitochondrial permeability transition pore (MPTP) and 
stimulation of uncoupling proteins (UCPs). This results in an elevated production of ATP by 
oxidative phosphorylation (OXIPHOS). These effects will also depend on its local synthesis 
(tryptophan (Trp) → serotonin (5TH) → melatonin (Mlt)) and metabolism. NQO2, quinone 
reductase 2; ROS, reactive oxygen species, RNS, reactive nitrogen species.
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Figure 2. Topically or orally administered melatonin affects different skin functions
To compensate inadequate intracutaneous levels of melatonin secondary to environmentally 
induced degradation or suboptimal local production or transport from the pineal gland, 
melatonin can be delivered to the skin via different routes. Orally ingested melatonin is 
rapidly metabolized in the liver by CYP450 into 6-hydroxymelatonin while sublingual 
(transmucosal) melatonin administration can bypass liver metabolism. Transdermal 
application of melatonin appears to be optimal for local application due to slow absorption, 
deposition in the skin, lack of identifiable site effects, and availability of different 
formulations (Flo et al., 2016, 2017; Milan et al., 2017; Romic et al., 2016; Scheuer et al., 
2016b; Zetner et al., 2016). Because there is a cutaneous melatonin metabolism with 
metabolites sharing similar activities as melatonin (Slominski et al., 2017b), the effects 
summarized in the central column may also be secondary to the action of its metabolites. Of 
note, 6-hydroxymelatonin, 4-hydroxymelatonin, 2-hydroxymelatonin, AFMK, or AMK 
being produced by different species, in addition to the human body, may fulfill the definition 
of natural products for topical applications to improve healthy skin status. Importantly, the 
functional effects depicted here may also be exerted by endogenous melatonin synthesized 
in the skin and hair follicles (see main text). AFMK, N1-acetyl-N2-formyl-5-
methoxykynuramine; AMK, N1-acetyl-5-methoxykynuramine; CYP, cytochrome P450.
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